Cited by 71Ubiquitin and proteasome pathwaysProtein Degradation and InhibitorsComputational Drug Discovery Methods

Identification and structure-guided development of pyrimidinone based USP7 inhibitors

Open access
O’Dowd, Colin R., Helm, Matthew D., Rountree, J. S. Shane, Flasz, Jakub T., Arkoudis, Elias, Miel, Hugues, Hewitt, Peter R., Jordan, Linda +11 more·2018·ACS Medicinal Chemistry Letters

Abstract

Ubiquitin specific protease 7 (USP7, HAUSP) has become an attractive target in drug discovery due to the role it plays in modulating Mdm2 levels and consequently p53. Increasing interest in USP7 is emerging due to its potential involvement in oncogenic pathways as well as possible roles in both metabolic and immune disorders in addition to viral infections. Potent, novel, and selective inhibitors of USP7 have been developed using both rational and structure-guided design enabled by high-resolution cocrystallography. Initial hits were identified via fragment-based screening, scaffold-hopping, and hybridization exercises. Two distinct subseries are described along with associated structure–activity relationship trends, as are initial efforts aimed at developing compounds suitable for in vivo experiments. Overall, these discoveries will enable further research into the wider biological role of USP7.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsmedchemlett.7b00512

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Compound 46 binds a few angstroms from the active site residues of USP7.

    “Similarly, the non-covalent pyrimidine-based USP7 inhibitor Compound 46 binds a few angstroms from the active site residues (O’Dowd et al., 2018).”

    From USP7 Is a Master Regulator of Genome Stability (2020) · cites this paper as O’Dowd et al., 2018

  • Compound 46 is a non-covalent pyrimidine-based USP7 inhibitor.

    “Similarly, the non-covalent pyrimidine-based USP7 inhibitor Compound 46 binds a few angstroms from the active site residues (O’Dowd et al., 2018).”

    From USP7 Is a Master Regulator of Genome Stability (2020) · cites this paper as O’Dowd et al., 2018

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
O’Dowd, C. R., Helm, M. D., Rountree, J. S. S., Flasz, J. T., Arkoudis, E., Miel, H., Hewitt, P. R., Jordan, L., Barker, O., Hughes, C., Rozycka, E., Cassidy, E., McClelland, K., Odrzywol, E., Page, N., Feutren-Burton, S., Dvorkin, S., Gavory, G., & Harrison, T.
Affiliations
  • Almac Discovery Ltd., Centre for Precision Therapeutics, 97 Lisburn Road, Belfast, Northern Ireland BT9 7AE, United Kingdom
  • Almac (United Kingdom) (GB)
  • Queen's University Belfast (GB)
Venue
ACS Medicinal Chemistry Letters
Published
2018-02-21
Volume
9
Issue
3
Pages
238-243
ISSN
1948-5875 (ISSN-L)
OpenAlex
W2788145402
Cited by
71
References
22
Citations by year
2026: 8 · 2025: 13 · 2024: 7 · 2023: 4 · 2022: 11 · 2021: 7 · 2020: 12 · 2019: 6 · 2018: 3
FWCI
2.67
Type
journal article
Language
en
Open access
Locations
  • ACS Medicinal Chemistry Letters (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (Queen's University Belfast) (acceptedVersion, other-oa)
Funders
  • European Regional Development Fund
  • Almac Group
  • Invest Northern Ireland (RD1010668)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
Keywords
USP7, MDM2, p53, structure-based drug design, fragment screening, scaffold hopping, hybridization, structure-activity relationship, oncogenic signaling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review